CIM Securities analyst Kumaraguru Raja maintained a Buy rating on Histogenics (NASDAQ: HSGX) on September 10 and set a price target of $1.50. The company’s shares closed yesterday at $0.66, close to its 52-week low of $0.60.
According to TipRanks.com, Raja is ranked #3807 out of 4870 analysts.
Currently, the analyst consensus on Histogenics is a Strong Buy with an average price target of $2.50, which is a 278.5% upside from current levels. In a report issued on September 5, H.C. Wainwright also reiterated a Buy rating on the stock with a $2 price target.
.
See today’s analyst top recommended stocks >>
Based on Histogenics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.78 million. In comparison, last year the company had a GAAP net loss of $6.54 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Histogenics Corp. engages in the development, marketing, and commercialization of musculoskeletal medicine. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.
